AU704160B2 - Freeze-dried ondansetron compositions - Google Patents

Freeze-dried ondansetron compositions Download PDF

Info

Publication number
AU704160B2
AU704160B2 AU41739/96A AU4173996A AU704160B2 AU 704160 B2 AU704160 B2 AU 704160B2 AU 41739/96 A AU41739/96 A AU 41739/96A AU 4173996 A AU4173996 A AU 4173996A AU 704160 B2 AU704160 B2 AU 704160B2
Authority
AU
Australia
Prior art keywords
ondansetron
freeze
free base
composition according
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU41739/96A
Other languages
English (en)
Other versions
AU4173996A (en
Inventor
Ian Keith Winterborn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aspen Global Inc
Original Assignee
Glaxo Wellcome Inc Canada
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10764757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU704160(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Wellcome Inc Canada, Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc Canada
Publication of AU4173996A publication Critical patent/AU4173996A/en
Application granted granted Critical
Publication of AU704160B2 publication Critical patent/AU704160B2/en
Assigned to ASPEN GLOBAL INCORPORATED reassignment ASPEN GLOBAL INCORPORATED Alteration of Name(s) in Register under S187 Assignors: GLAXO WELLCOME INC.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Detergent Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Fertilizers (AREA)
AU41739/96A 1994-11-22 1995-11-20 Freeze-dried ondansetron compositions Expired AU704160B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9423511A GB9423511D0 (en) 1994-11-22 1994-11-22 Compositions
GB9423511 1994-11-22
PCT/EP1995/004550 WO1996015785A1 (en) 1994-11-22 1995-11-20 Freeze-dried ondansetron compositions

Publications (2)

Publication Number Publication Date
AU4173996A AU4173996A (en) 1996-06-17
AU704160B2 true AU704160B2 (en) 1999-04-15

Family

ID=10764757

Family Applications (1)

Application Number Title Priority Date Filing Date
AU41739/96A Expired AU704160B2 (en) 1994-11-22 1995-11-20 Freeze-dried ondansetron compositions

Country Status (30)

Country Link
US (2) US5955488A (enExample)
EP (1) EP0793495B1 (enExample)
JP (1) JP3001264B2 (enExample)
KR (1) KR970706814A (enExample)
CN (1) CN1080118C (enExample)
AT (1) ATE193444T1 (enExample)
AU (1) AU704160B2 (enExample)
BE (1) BE1010250A3 (enExample)
BR (1) BR9509808A (enExample)
CY (1) CY2166B1 (enExample)
CZ (1) CZ285250B6 (enExample)
DE (1) DE69517332T2 (enExample)
DK (1) DK0793495T3 (enExample)
ES (1) ES2147309T3 (enExample)
FI (1) FI119355B (enExample)
FR (1) FR2727016B1 (enExample)
GB (2) GB9423511D0 (enExample)
GR (1) GR3033937T3 (enExample)
HU (1) HU226891B1 (enExample)
IL (1) IL116084A (enExample)
IT (1) IT1282352B1 (enExample)
MX (1) MX9703735A (enExample)
NO (1) NO306893B1 (enExample)
NZ (1) NZ296982A (enExample)
PL (1) PL181179B1 (enExample)
PT (1) PT793495E (enExample)
RU (1) RU2159614C2 (enExample)
TW (1) TW398976B (enExample)
WO (1) WO1996015785A1 (enExample)
ZA (1) ZA959821B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976577A (en) * 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
WO1999016417A1 (en) * 1997-10-01 1999-04-08 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
US20040136914A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US6630006B2 (en) * 1999-06-18 2003-10-07 The Regents Of The University Of California Method for screening microcrystallizations for crystal formation
AU2023401A (en) * 1999-12-01 2001-06-12 Natco Pharma Limited A rapid acting freeze dired oral pharmaceutical composition for treating migraine
RU2162847C1 (ru) * 2000-07-14 2001-02-10 ООО с иностранными инвестициями "Редди-Биомед лимитед" Способ получения ондансетрона и его фармацевтически приемлемых солей
SK6182003A3 (en) * 2000-10-30 2004-03-02 Teva Pharma Crystalline and solvated forms of ondansetrone hydrochloride and preparation thereof
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
ATE364611T1 (de) * 2002-04-29 2007-07-15 Teva Gyogyszergyar Zartkoeruee Verfahren zur herstellung von 1,2,3,9-tetrahydro- 9-methyl-3- (2-methyl-1h-imidazol-1-yl)methylö- h-carbazol-4-on
HRP20041136A2 (en) * 2002-04-30 2005-04-30 Teva Gy�gyszergy�r R�szv�nyt�rsas�g Novel crystal forms of ondansetron, processes fortheir preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
JP5690461B2 (ja) * 2002-11-15 2015-03-25 ヘルシン ヘルスケア ソシエテ アノニム 化学療法誘導嘔吐を治療するためのパロノセトロン
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
JP2007508271A (ja) 2003-10-10 2007-04-05 シントン・ベスローテン・フェンノートシャップ 固体状態のモンテルカスト
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
ATE504588T1 (de) * 2004-01-27 2011-04-15 Synthon Bv Stabile salze von olanzapin
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
US7501517B2 (en) * 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
US7829716B2 (en) * 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
EP2168975A3 (en) * 2004-05-24 2012-01-11 Genvault Corporation Method of stably storing biomolecules in recoverable form
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
WO2007020080A1 (en) * 2005-08-17 2007-02-22 Synthon B.V. A process for making olanzapine form i
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
AR057909A1 (es) * 2005-11-18 2007-12-26 Synthon Bv Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
WO2007107297A1 (en) * 2006-03-17 2007-09-27 Synthon B.V. Montelukast amantadine salt
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
US20080138409A1 (en) * 2006-09-29 2008-06-12 Osinga Niels J Olanzapine pharmaceutical composition
US8653066B2 (en) 2006-10-09 2014-02-18 Charleston Laboratories, Inc. Pharmaceutical compositions
EA016455B1 (ru) * 2006-10-24 2012-05-30 Хелсинн Хелткэр С.А. Мягкие капсулы, содержащие палоносетрона гидрохлорид, имеющие улучшенную стабильность и биологическую доступность
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
RU2363463C1 (ru) * 2007-11-14 2009-08-10 Федеральное государственное унитарное предприятие Научно-производственный центр "Фармзащита" Федерального медико-биологического агентства Лекарственное средство
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
CN102046602A (zh) * 2008-04-25 2011-05-04 斯索恩有限公司 制备孟鲁司特中间体的方法
EP2432467B1 (en) * 2009-05-20 2018-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin 5-ht3 receptor antagonists for use in the treatment of lesional vestibular disorders
ES2432618T3 (es) * 2009-05-20 2013-12-04 Inserm (Institut National De La Santé Et De La Recherche Medicale) Antagonistas del receptor 5-HT3 de serotonina para usar en el tratamiento o prevención de una patología del oído interno con déficit vestibular
EP2451274B1 (en) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmaceutical compositions
US10172833B2 (en) 2015-08-11 2019-01-08 Insys Development Company, Inc. Sublingual ondansetron spray
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
HRP20240453T1 (hr) 2016-04-14 2024-06-21 Sensorion (+)-azasetron za uporabu u liječenju poremećaja uha

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3275121D1 (en) * 1981-12-11 1987-02-19 Wyeth John & Brother Ltd Process for preparing solid shaped articles
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
GB8917556D0 (en) * 1989-08-01 1989-09-13 Glaxo Group Ltd Medicaments
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
JPH0648960A (ja) * 1990-02-22 1994-02-22 Glaxo Group Ltd 医 薬
US5046618A (en) * 1990-11-19 1991-09-10 R. P. Scherer Corporation Child-resistant blister pack

Also Published As

Publication number Publication date
GB9423511D0 (en) 1995-01-11
NO306893B1 (no) 2000-01-10
ZA959821B (en) 1996-07-31
CN1171741A (zh) 1998-01-28
ITRM950762A1 (it) 1997-05-20
IT1282352B1 (it) 1998-03-20
KR970706814A (ko) 1997-12-01
PL320295A1 (en) 1997-09-15
GB2295318B (en) 1998-10-28
CZ285250B6 (cs) 1999-06-16
FI119355B (fi) 2008-10-31
GB2295318A (en) 1996-05-29
JP3001264B2 (ja) 2000-01-24
ITRM950762A0 (enExample) 1995-11-20
HUT77886A (hu) 1998-09-28
FR2727016A1 (fr) 1996-05-24
IL116084A (en) 2000-01-31
NO972325D0 (no) 1997-05-21
PL181179B1 (pl) 2001-06-29
NZ296982A (en) 1998-06-26
HU226891B1 (en) 2010-01-28
ES2147309T3 (es) 2000-09-01
DE69517332T2 (de) 2000-11-30
PT793495E (pt) 2000-10-31
JPH10508864A (ja) 1998-09-02
CY2166B1 (en) 2002-08-23
EP0793495B1 (en) 2000-05-31
NO972325L (no) 1997-05-22
AU4173996A (en) 1996-06-17
DE69517332D1 (de) 2000-07-06
GR3033937T3 (en) 2000-11-30
BE1010250A3 (fr) 1998-04-07
CN1080118C (zh) 2002-03-06
BR9509808A (pt) 1997-10-21
RU2159614C2 (ru) 2000-11-27
FI972167A0 (fi) 1997-05-21
WO1996015785A1 (en) 1996-05-30
ATE193444T1 (de) 2000-06-15
US5955488A (en) 1999-09-21
EP0793495A1 (en) 1997-09-10
TW398976B (en) 2000-07-21
HK1009591A1 (en) 1999-06-04
FI972167L (fi) 1997-05-21
IL116084A0 (en) 1996-01-31
MX9703735A (es) 1998-07-31
US6063802A (en) 2000-05-16
FR2727016B1 (fr) 1998-04-03
CZ154997A3 (en) 1997-10-15
DK0793495T3 (da) 2000-10-09
GB9523667D0 (en) 1996-01-24

Similar Documents

Publication Publication Date Title
EP0793495B1 (en) Freeze-dried ondansetron compositions
AU703932B2 (en) Oral compositions containing ondansetron
US20050084530A1 (en) Rapid acting freeze dried oral pharmaceutical composition for treating migraine
EP0788789A1 (en) Ranitidine compositions and their use for the treatment of minor gastrointestinal disorders associated with excess acid secretion
UA51615C2 (uk) Застосування сполуки, що має капа опіатагоністичну активність та спосіб лікування
CA2205600C (en) Freeze-dried ondansetron compositions
JPH01316319A (ja) 医薬
MXPA97003734A (en) Oral compositions containing ondanset
HK1049619B (en) Oral solution containing galanthamine and a sweetening agent